0.05Open0.03Pre Close100 Volume159 Open Interest6.00Strike Price500.00Turnover256.93%IV21.40%PremiumDec 13, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0780Delta0.1102Gamma151.40Leverage Ratio-0.0449Theta0.0000Rho-11.81Eff Leverage0.0008Vega
Recursion Pharmaceuticals Stock Discussion
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class Cdk7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
No comment yet